TOKYO, JAPAN - August 6, 2018 - Terumo Corporation (TSE: 4543) today announced that WEGO Terumo (Weihai) Medical Products Co., Ltd, its affiliated company in China, received an approval to manufacture and sell peritoneal dialysis (PD) solution in July.
The affiliated company was established as a joint venture of WEGO Blood Purification Products Co., Ltd and Terumo. With the conclusion of the approval, the company will start to manufacture PD solution and related medical devices. WEGO group plans to launch those products in 2018. Terumo provides the affiliated company with technology and trademark license. Furthermore, Terumo gives marketing support to a WEGO group company which sells products and operates after-sales services.
With the strategic business alliance with WEGO group, Terumo aims for further PD dissemination in the fast growing Chinese dialysis market, by combining Terumo's technology and expertise in PD and WEGO's strong market presence with nationwide sales network.
Notes: Terumo's PD business
Terumo has been promoting the dissemination and expansion of PD since the company began the development of PD system in 1980. Terumo has been leading this field in Japan by providing innovation including Japan's first neutralized dialysate.
Notes: The Chinese dialysis market
In China, approximately 3,000,000 people are suffering from End-Stage Renal Disease (ESRD). The figure is estimated to reach approximately 4,500,000 within the next 10 years. Over 80,000 ESRD patients are currently receiving Peritoneal Dialysis (PD) therapy, forming the world largest PD market. The PD patient population is estimated to reach approximately 200,000 within the next 10 years.
*The numbers are estimated by WEGO
Notes: Terumo's regional strategy for China
Terumo has pursued its strategy in each region appropriately to the local market and its position there, while globalizing uniformly under business-led management. Terumo has moved to localize its business in China, entering into alliances with local players in selected fields, including renal denervation catheters and neuroendovascular therapy. In July 2018, Terumo entered into an agreement to acquire a specialized enterprise of drug-eluting stents in the field of coronary intervention.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.